NCT07940244
A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or Obesity
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
Timeframe: Up to Day 239
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)
Timeframe: Up to Day 239
Arms and interventions
BI 456906 formulation A (Reference) then BI 456906 formulation D1 (Test)Experimental
Subcutaneous administration of formulation A (Reference) then formulation D1 (Test)
BI 456906 formulation D1 (Test) then BI 456906 formulation A (Reference)Experimental
Subcutaneous administration of formulation D1 (Test) then formulation A (Reference)
Combination products: Survodutide formulation A, Survodutide formulation D1
Sites
1 site in 1 country
- hVIVO MannheimMannheim, Germany